✉ info@591daili.com☎ +86-18553102138
📞 WhatsApp中文
圣和化工
Home › Product Catalog › Atazanavir

Atazanavir

CAS 198904-31-3C38H52N6O7MW 704.9

Atazanavir (CAS No. 198904-31-3) is supplied by Jinan Shenghe Chemical Co., Ltd. with a typical purity of 按批次COA提供(不公开发布). Main applications include Pharmaceutical Intermediates & APIs. Bulk quantities are available with COA; purity and packaging are subject to batch COA and order confirmation.

Specifications

CAS Number198904-31-3
Molecular FormulaC38H52N6O7
Molecular Weight704.9
LogP4.5
Purity按批次COA提供(不公开发布)
Packaging按订单/批次确认(不公开发布)
ApplicationsPharmaceutical Intermediates & APIs
CategoryPharmaceutical Intermediates & APIs

Where it is used

Pharmaceutical Intermediates & APIs

Packaging & Supply

Packaging按订单/批次确认(不公开发布)
Purity按批次COA提供(不公开发布)
StorageSealed, cool and dry place
Lead TimeIn stock / per order

Documents & Support

COA provided with every batch; MSDS and technical documents available on request. Email us with product name and CAS number for a quote within one business day.

Frequently Asked Questions

What is the CAS number of Atazanavir?

The CAS number of Atazanavir is 198904-31-3.

What purity and packaging are available?

Typical purity is 按批次COA提供(不公开发布), supplied in 按订单/批次确认(不公开发布), with COA provided.

What are the applications of Atazanavir?

Main applications include Pharmaceutical Intermediates & APIs.

How do I buy Atazanavir or get a quote?

Email info@591daili.com or reach us on WhatsApp with the product name, CAS number and required quantity; quotes within one business day. Supplier: Jinan Shenghe Chemical Co., Ltd..

PubChem Public Data

Description

Atazanavir · CAS 198904-31-3 · C38H52N6O7. UNII QZU4H47A3S. Solubility: 3.27e-03 g/L; LogP: 4.5.

Identification

CAS Registry Number198904-31-3
PubChem CID148192
Molecular formulaC38H52N6O7
IUPAC namemethyl N-[(2S)-1-[2-[(2S,3S)-2-hydroxy-3-[[(2S)-2-(methoxycarbonylamino)-3,3-dimethylbutanoyl]amino]-4-phenylbutyl]-2-[(4-pyridin-2-ylphenyl)methyl]hydrazinyl]-3,3-dimethyl-1-oxobutan-2-yl]carbamate
UNII (FDA)QZU4H47A3S

Computed Descriptors

Molecular Weight704.9
XLogP35.6
Hydrogen Bond Donor Count5
Hydrogen Bond Acceptor Count9
Rotatable Bond Count18
Exact Mass704.38974802
Monoisotopic Mass704.38974802
Topological Polar Surface Area171
Heavy Atom Count51
Formal Charge0

Physical & Chemical Properties

Solubility3.27e-03 g/L
LogP4.5

Physical description & handling notes

  • Solid
  • Free base slightly soluble (4-5 mg/mL)
  • White to pale yellow crystalline powder. Slightly soluble in water 4-5 mg/mL. pH of saturated solution 1.9 at 24 °C. /Sulfate salt/
  • Oral: Capsules: 100 mg (of atazanavir) Reyataz, (Bristol-Myers Squibb), 150 mg (of atazanavir) Reyataz, (Bristol-Myers Squibb), 200 mg (of atazanavir) Reyataz, (Bristol-Myers Squibb).

GHS Hazard Classification

Reported hazard statementsH318 (66.7%), H319 (33.3%), H372 (66.7%), H411 (66.7%)

H318 (66.7%): Causes serious eye damage [Danger Serious eye damage/eye irritation]

H319 (33.3%): Causes serious eye irritation [Warning Serious eye damage/eye irritation]

Documented Uses

  • Human immunodeficiency virus (HIV) infection (treatment). Atazanavir sulfate is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. /Atazanavir Sulfate/
  • Use (kg; approx.) in Germany (2009): >500
  • Consumption (g per capita; approx.) in Germany (2009): 0.00611
  • Atazanavir is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older weighing at least 5kg. Atazanavir is also indicated in combination with [cobicistat] and other antiretrovirals for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 35kg.
  • Atazanavir is an antiretroviral protease inhibitor that is used in the therapy and prevention of human immunodeficiency virus (HIV-1) infection and the acquired immunodeficiency syndrome (AIDS). Atazanavir can cause transient and usually asymptomatic elevations in serum aminotransferase levels, mild elevations in indirect bilirubin concentration and, rarely, clinically apparent, acute liver injury. In HBV or HCV coinfected patients, highly active antiretroviral therapy with atazanavir may result of an exacerbation
  • Breast Feeding; Lactation; Milk, Human; Anti-Infective Agents; Antiviral Agents; Anti-HIV Agents; Anti-Retroviral Agents; HIV Protease Inhibitors

Synonyms

Atazanavir; 198904-31-3; Latazanavir; Zrivada; BMS-232632; atazanavirum; DTXSID9048691; QZU4H47A3S; CHEBI:37924; DTXCID5028617; RefChem:54330; J05AE08; CGP 73547; CGP-73547; BMS 232632; Atazanavir Base

Frequently Asked Questions

What are the CAS number and molecular formula of Atazanavir?

CAS 198904-31-3; molecular formula C38H52N6O7; molecular weight — g/mol.

What other names is Atazanavir known by?

Atazanavir, 198904-31-3, Latazanavir, Zrivada, BMS-232632, atazanavirum.

Is Atazanavir classified as hazardous?

Hazard statements reported: H318, H319, H372, H411.

What are the key physical properties of Atazanavir?

Solubility: 3.27e-03 g/L; LogP: 4.5.

Facts on this page are taken from PubChem (US National Library of Medicine) and Wikidata. Grade-specific data — assay, moisture, particle size, packaging, shelf life — is issued per batch on the COA and is not published here.

You may also need

acycloguanosineCAS 59277-89-3›
AtenololCAS 29122-68-7›
AcetamideCAS 60-35-5›
AdenineCAS 73-24-5›
AmpicillinCAS 69-53-4›
AzithromycinCAS 83905-01-5›
Amoxicillin trihydrateCAS 61336-70-7›
Atorvastatin CalciumCAS 134523-03-8›

Get a quote for Atazanavir

Supplier: Jinan Shenghe Chemical Co., Ltd. · Reply within one business day.

Email Inquiry WhatsApp
鲁ICP备19031700号-1